Why the study?
Does a new implantable programmable insulin pump provide safe and effective long-term intraperitoneal insulin delivery in diabetic dogs?
Does a new implantable programmable insulin pump provide safe and effective long-term intraperitoneal insulin delivery in diabetic dogs?
Answers are grounded in this paper and cite their sources.
A new implantable programmable insulin pump with a sideport allows for safe long-term intraperitoneal insulin delivery and in-situ resolution of insulin precipitates in a canine model.
A positive-pressure implantable programmable pump with an integrated sideport and a detachable catheter was tested for long-term intraperitoneal insulin delivery in 2 diabetic dogs. Programming and refilling of the pump was simple and presented no problems during 28 months of pump function. During pump therapy an acceptable degree of glycemic control was maintained. No catheter occlusion occurred, and no skin erosions or infections were observed. Insulin in the pump reservoir was stable. After 9.5 months of pump function, flow progressively decreased because of insulin precipitation in the valved accumulator. Solubilization of these precipitates using 0.1 N NaOH injected in the reservoir and drained through the sideport normalized pump delivery rates. We conclude that this device is safe for long-term intraperitoneal insulin delivery. The sideport enables discrimination between different causes of pump malfunction and allows for the safe use of an alkaline solution to remove insulin precipitates, thus avoiding pump explantation.
No takes yet. Share an insight, caveat, or question.
Scavini et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: